FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1553043283> ?p ?o ?g. }

• W1553043283 abstract "Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage). This review updates a review published in 2014, and previous reviews published in 2011, 2005 and 2000.To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain in adults.For this update we searched CENTRAL), MEDLINE, and Embase for randomised controlled trials from January 2014 to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trials registries.We included randomised, double-blind trials of two weeks' duration or longer, comparing gabapentin (any route of administration) with placebo or another active treatment for neuropathic pain, with participant-reported pain assessment.Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)), or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC). We performed a pooled analysis for any substantial or moderate benefit. Where pooled analysis was possible, we used dichotomous data to calculate risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNT) or harmful outcome (NNH). We assessed the quality of the evidence using GRADE and created 'Summary of findings' tables.We included four new studies (530 participants), and excluded three previously included studies (126 participants). In all, 37 studies provided information on 5914 participants. Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy. Study duration was typically four to 12 weeks. Not all studies reported important outcomes of interest. High risk of bias occurred mainly due to small size (especially in cross-over studies), and handling of data after study withdrawal.In postherpetic neuralgia, more participants (32%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (17%) (RR 1.8 (95% CI 1.5 to 2.1); NNT 6.7 (5.4 to 8.7); 8 studies, 2260 participants, moderate-quality evidence). More participants (46%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (25%) (RR 1.8 (95% CI 1.6 to 2.0); NNT 4.8 (4.1 to 6.0); 8 studies, 2260 participants, moderate-quality evidence).In painful diabetic neuropathy, more participants (38%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (21%) (RR 1.9 (95% CI 1.5 to 2.3); NNT 5.9 (4.6 to 8.3); 6 studies, 1277 participants, moderate-quality evidence). More participants (52%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (37%) (RR 1.4 (95% CI 1.3 to 1.6); NNT 6.6 (4.9 to 9.9); 7 studies, 1439 participants, moderate-quality evidence).For all conditions combined, adverse event withdrawals were more common with gabapentin (11%) than with placebo (8.2%) (RR 1.4 (95% CI 1.1 to 1.7); NNH 30 (20 to 65); 22 studies, 4346 participants, high-quality evidence). Serious adverse events were no more common with gabapentin (3.2%) than with placebo (2.8%) (RR 1.2 (95% CI 0.8 to 1.7); 19 studies, 3948 participants, moderate-quality evidence); there were eight deaths (very low-quality evidence). Participants experiencing at least one adverse event were more common with gabapentin (63%) than with placebo (49%) (RR 1.3 (95% CI 1.2 to 1.4); NNH 7.5 (6.1 to 9.6); 18 studies, 4279 participants, moderate-quality evidence). Individual adverse events occurred significantly more often with gabapentin. Participants taking gabapentin experienced dizziness (19%), somnolence (14%), peripheral oedema (7%), and gait disturbance (14%).Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by patients, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. Around 3 or 4 out of 10 participants achieved this degree of pain relief with gabapentin, compared with 1 or 2 out of 10 for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief but may experience adverse events. Conclusions have not changed since the previous update of this review." @default.
• W1553043283 created "2016-06-24" @default.
• W1553043283 creator A5010590729 @default.
• W1553043283 creator A5038998860 @default.
• W1553043283 creator A5045837144 @default.
• W1553043283 creator A5054478282 @default.
• W1553043283 creator A5077191679 @default.
• W1553043283 creator A5083618919 @default.
• W1553043283 creator A5084871131 @default.
• W1553043283 date "2017-06-09" @default.
• W1553043283 modified "2023-10-17" @default.
• W1553043283 title "Gabapentin for chronic neuropathic pain in adults" @default.
• W1553043283 cites W1482483586 @default.
• W1553043283 cites W1488655318 @default.
• W1553043283 cites W1496322206 @default.
• W1553043283 cites W1517417769 @default.
• W1553043283 cites W1521695277 @default.
• W1553043283 cites W1560046035 @default.
• W1553043283 cites W1580757321 @default.
• W1553043283 cites W1582528366 @default.
• W1553043283 cites W1589453396 @default.
• W1553043283 cites W1609116925 @default.
• W1553043283 cites W1636329876 @default.
• W1553043283 cites W1802133245 @default.
• W1553043283 cites W1822171213 @default.
• W1553043283 cites W1873305365 @default.
• W1553043283 cites W1899609246 @default.
• W1553043283 cites W1910061082 @default.
• W1553043283 cites W1918653894 @default.
• W1553043283 cites W1926546914 @default.
• W1553043283 cites W1943094646 @default.
• W1553043283 cites W1947262708 @default.
• W1553043283 cites W1960053172 @default.
• W1553043283 cites W1963892924 @default.
• W1553043283 cites W1964065290 @default.
• W1553043283 cites W1969554594 @default.
• W1553043283 cites W1970186596 @default.
• W1553043283 cites W1972991130 @default.
• W1553043283 cites W1974361246 @default.
• W1553043283 cites W1975340066 @default.
• W1553043283 cites W1976066489 @default.
• W1553043283 cites W1976875716 @default.
• W1553043283 cites W1977521225 @default.
• W1553043283 cites W1981093359 @default.
• W1553043283 cites W1981435820 @default.
• W1553043283 cites W1982534727 @default.
• W1553043283 cites W1982924223 @default.
• W1553043283 cites W1983749224 @default.
• W1553043283 cites W1985502152 @default.
• W1553043283 cites W1986215651 @default.
• W1553043283 cites W1988452935 @default.
• W1553043283 cites W1995021873 @default.
• W1553043283 cites W1995051534 @default.
• W1553043283 cites W1999346159 @default.
• W1553043283 cites W2004791658 @default.
• W1553043283 cites W2005625267 @default.
• W1553043283 cites W2007075809 @default.
• W1553043283 cites W2008046082 @default.
• W1553043283 cites W2008775818 @default.
• W1553043283 cites W2008877403 @default.
• W1553043283 cites W2009529491 @default.
• W1553043283 cites W2009996604 @default.
• W1553043283 cites W2010942808 @default.
• W1553043283 cites W2014421192 @default.
• W1553043283 cites W2014657120 @default.
• W1553043283 cites W2014670473 @default.
• W1553043283 cites W2015233162 @default.
• W1553043283 cites W2015824469 @default.
• W1553043283 cites W2016474170 @default.
• W1553043283 cites W2019875673 @default.
• W1553043283 cites W2019968234 @default.
• W1553043283 cites W2020576395 @default.
• W1553043283 cites W2021630340 @default.
• W1553043283 cites W2023541450 @default.
• W1553043283 cites W2030479880 @default.
• W1553043283 cites W2033223166 @default.
• W1553043283 cites W2034818081 @default.
• W1553043283 cites W2036949225 @default.
• W1553043283 cites W2037520119 @default.
• W1553043283 cites W2039291051 @default.
• W1553043283 cites W2039824535 @default.
• W1553043283 cites W2039982019 @default.
• W1553043283 cites W2041635174 @default.
• W1553043283 cites W2042741271 @default.
• W1553043283 cites W2047074966 @default.
• W1553043283 cites W2047586716 @default.
• W1553043283 cites W2048143950 @default.
• W1553043283 cites W2048800165 @default.
• W1553043283 cites W2055846831 @default.
• W1553043283 cites W2056698071 @default.
• W1553043283 cites W2057983296 @default.
• W1553043283 cites W2060579001 @default.
• W1553043283 cites W2062864603 @default.
• W1553043283 cites W2063738853 @default.
• W1553043283 cites W2064914903 @default.
• W1553043283 cites W2065306248 @default.
• W1553043283 cites W2066589648 @default.
• W1553043283 cites W2068986853 @default.
• W1553043283 cites W2071357308 @default.
• W1553043283 cites W2071419929 @default.

• next